Alumis Inc (ALMS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alumis Inc (ALMS) has a cash flow conversion efficiency ratio of -0.239x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-71.91 Million) by net assets ($301.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Alumis Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Alumis Inc - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Alumis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alumis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alumis Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enerjisa Enerji AS
IS:ENJSA
|
0.063x |
|
AIR FRANCE-KLM ADR EO 85
F:FQZ
|
0.525x |
|
Steven Madden Ltd
NASDAQ:SHOO
|
-0.058x |
|
An Hui Wenergy Co Ltd
SHE:000543
|
0.126x |
|
Jiangsu Ruitai New Energy Materials Co. Ltd.
SHE:301238
|
0.027x |
|
Medical Properties Trust, Inc.
NYSE:MPT
|
-0.003x |
|
NH Hoteles
MC:NHH
|
0.219x |
|
Digital China Group Co Ltd
SHE:000034
|
-0.106x |
Annual Cash Flow Conversion Efficiency for Alumis Inc (2022–2025)
The table below shows the annual cash flow conversion efficiency of Alumis Inc from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Alumis Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $301.30 Million | $-369.52 Million | -1.226x | -25.06% |
| 2024-12-31 | $260.10 Million | $-255.08 Million | -0.981x | -355.98% |
| 2023-12-31 | $-339.26 Million | $-129.97 Million | 0.383x | -30.56% |
| 2022-12-31 | $-195.24 Million | $-107.72 Million | 0.552x | -- |
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment o… Read more